StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Wall Street bullish on Cytokinetics (CYTK) following positive trial results
December 28, 2023 7:55 AM
Cytokinetics (NASDAQ: CYTK) shares surged more than 82% Wednesday on the back of the positive results from its experimental heart ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Hot List
Next Articles
Cytokinetics (CYTK) PT Raised to $94 at H.C. Wainwright
December 28, 2023 6:35 AM
Cytokinetics (CYTK) PT Raised to $85 at Goldman Sachs
December 28, 2023 5:44 AM
Cytokinetics (CYTK) January calls and puts active
December 28, 2023 5:08 AM
Cytokinetics (CYTK) PT Raised to $86 at Truist, 'recent data further support CYTK as an attractive M&A target'
December 27, 2023 1:43 PM
Cytokinetics (CYTK) PT Raised to $107 at Oppenheimer, 'We Stay Bullish'
December 27, 2023 1:42 PM
Mizuho on Cytokinetics (CYTK): 'Investors will now likely shift the debate back to M&A'
December 27, 2023 9:21 AM
Truist on Cytokinetics (CYTK): 'We See Best In Class Potential for aficamten'
December 27, 2023 9:20 AM
B.Riley on Cytokinetics (CYTK): 'Remain Buyers'
December 27, 2023 9:18 AM
Cytokinetics (CYTK) Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
December 27, 2023 7:30 AM
Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
December 27, 2023 7:30 AM
